ABSTRACT
This study evaluates clinical, virological and immunological responses to antiretroviral (ARV) therapy based on Lopinavir/ritonovir (LPV/r) in previously protease -inhibitor-experienced children. The study included 29 Brazilian children (median age = 5.91 years) who had failed previous ARV therapy and had begun a regimen based on LPV/r. At 12 months follow-up, a good virological response to LPV/r therapy was defined as achieving an undetectable viral load or as a decrease in plasma HIV RNA levels to > 1 log. A good immunological response was defined as an increase in CD4+ cell count from baseline sufficient to attain a better CDC immune stage classification. The number of infectious episodes 12 months before and 12 months after beginning LPV/r was assessed. Sixteen (55.2 percent) and 19 (65.5 percent) of 29 patients exhibited good virological and immunological responses, respectively. Baseline CD4+ values (>500) predicted both virological and immunological responses (p<0.05). Older children were less likely to develop an immunological response (p<0.001) than younger children. Nine children receiving 3 ARV drugs plus LPV/r showed an immunological response (100 percent) compared to 10/20 (50 percent) children receiving 2 drugs plus LPV/r (p=0.01). A lower number (n<5) of infectious episodes was noted after 12 months follow-up in children using the LPV/r regimen (p=0.006). There was a positive correlation between children whose baseline CD4+ values were greater than 500 cells/mm³ and virological responses. Although virological responses to therapy were seen in about half the children (55.2 percent), the use of HAART containing LPV/r provided clinical and immmunological benefits.
Subject(s)
Child , Child, Preschool , Humans , Antiretroviral Therapy, Highly Active , Acquired Immunodeficiency Syndrome/drug therapy , HIV Protease Inhibitors/therapeutic use , Pyrimidinones/therapeutic use , Ritonavir/therapeutic use , Acquired Immunodeficiency Syndrome/immunology , Acquired Immunodeficiency Syndrome/virology , Follow-Up Studies , Longitudinal Studies , RNA, Viral , Treatment Outcome , Viral LoadABSTRACT
Objetivo: Enfatizar aspectos importantes para o diagnóstico e manejo clínico de pacientes com actinomicose cervicofacial na infância. Casuística e método: O presente estudo é um relato de caso de actinomicose na forma cervicofacial, acompanhando de revisão da literatura dos últimos anos através dos bancos de dados Lilacs e Medline. Resultados: Paciente do sexo masculino acompanhado na enfermaria de moléstias infecciosas pediátricas por actinomicose cervicofacial. O diagnóstico foi realizado através de biópsia de nódulo cervical e isolamento da bactéria. O antibiótico utilizado foi a penicilina para o actimomices, por 14 dias. Alta após diminuição do nódulo, com orientação de amoxicilina por mínimo de 6 meses e acompanhamento ambulatorial. Conclusão: O diagnóstico precoce da actinomicose resulta em tratamento adequado e imediato, evitando-se o acometimento de áreas nobres em SNC, face e pescoço